Healthcare
Incyte Corporation(INCY)
Live Price
Offline$98.22
-0.78% today
1Y Change
+46.54%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $19.03B
- Revenue Growth
- +21.2%
- EPS Growth
- +4018.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Incyte Corporation (INCY) is a Healthcare stock with a market cap of $19.03B and listed on NASDAQ. The stock last traded around $98.22 and up 46.5% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +21.2%, EPS growth of +4018.8%, a dividend yield of 0.0%. What stands out right now is revenue +21.2%, EPS +4018.8%, free cash flow +443.9% with operating margin 26.8% and ROIC 20.0%. Valuation is more restrained than many high-expectation growth names at P/E 13.3 and price/sales 3.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines INCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.2% vs +7.6% peer median
Operating Margin
Above sector median
+26.8% vs +19.4% peer median
P/E
Below sector median
13.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +21.2% and EPS at +4018.8%, with operating margin around 26.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +2.4% | +1.7% | +0.5% |
2026 Feb 10, 2026 | -5.3% | -1.2% | +2.9% | -5.4% |
2025 Oct 28, 2025 | +36.1% | -1.6% | +12.3% | +15.2% |
Benchmark Edge
INCY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INCY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INCY Max Drawdown
-18.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INCY and SPY.
Company Overview
Incyte Corporation
NASDAQ Global Select
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Leadership
- William J. Meury
- IPO Date
- Nov 4, 1993
- Employees
- 2.6k
- Street Address
- 1801 Augustine Cut-Off
- Mailing
- Wilmington, DE, 19803
- Region
- Wilmington, DE, US
- Reporting Currency
- USD
- Investor Line
- 302 498 6700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 13.3
- EV/EBITDA
- 8.3
- Price/Sales
- 3.6
- Price/Book
- 3.4
Growth
- Revenue
- +21.2%
- EPS
- +4018.8%
- Free Cash Flow
- +443.9%
Profitability
- Gross Margin
- 91.9%
- Operating Margin
- 26.8%
- Net Margin
- 26.7%
- ROE
- 29.3%
- ROIC
- 20.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.68
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.